Strategic Collaborations, Clinical Studies, Regulatory Update, and Other Corporate Announcements - Research Report on OncoMed,

   Strategic Collaborations, Clinical Studies, Regulatory Update, and Other
    Corporate Announcements - Research Report on OncoMed, Auxilium Pharma,
            BioTelemetry, Progenics Pharma, and Ambit Biosciences

Editor Note: For more information about this release, please scroll to bottom.

PR Newswire

NEW YORK, December 9, 2013

NEW YORK, December 9, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting OncoMed
Pharmaceuticals, Inc. (NASDAQ: OMED), Auxilium Pharmaceuticals Inc. (NASDAQ:
AUXL), BioTelemetry Inc (NASDAQ: BEAT), Progenics Pharmaceuticals Inc.
(NASDAQ: PGNX), and Ambit Biosciences Corporation (NASDAQ: AMBI). Today's
readers may access these reports free of charge - including full price
targets, industry analysis and analyst ratings - via the links below.

OncoMed Pharmaceuticals, Inc. Research Report  

On December 3, 2013, OncoMed Pharmaceuticals Inc. (OncoMed) announced a
strategic collaboration with Celgene Corporation to jointly develop and
commercialize up to six anti-cancer stem cell (CSC) product candidates from
OncoMed's biologics pipeline, including demcizumab. OncoMed stated that it
will control and conduct initial clinical studies at which point Celgene has
an option to license worldwide rights to up to six novel anti-CSC therapeutic
candidates. According to the Company, OncoMed retains global co-development
and U.S. co-commercialization rights for five of the six anti-CSC product
candidates with 50/50 U.S. profit sharing, and royalties to be received in
other territories. Paul J. Hastings, OncoMed's Chairman and CEO said,
"Through this major alliance with Celgene, we gain substantial resources that
will enable us to continue to discover and develop new therapeutics
independently while positioning OncoMed for substantial potential downstream
value and profits. Importantly, by retaining co-development and
co-commercialization rights to up to five biologic product candidates in our
pipeline, we expect to add commercial capabilities to our core research and
development competencies as we continue to build a premier oncology
biotherapeutics company." The Full Research Report on OncoMed Pharmaceuticals,
Inc. - including full detailed breakdown, analyst ratings and price targets -
is available to download free of charge at:

http://analystscorner.com/microwriter/link.php?s=DDD

http://www.analystscorner.com/r/full_research_report/a95c_OMED

--

Auxilium Pharmaceuticals Inc. Research Report

On December 4, 2013, Auxilium Pharmaceuticals, Inc. (Auxilium) announced that
the United States District Court for the District of Delaware granted
Upsher-Smith Laboratories, Inc.'s motion for summary judgment with respect to
its attempts to bring a testosterone gel product to market via its 505(b)(2)
NDA using Auxilium's Testim® product as its reference listed drug. "We are
very disappointed with the Court's decision," said Adrian Adams, CEO and
President of Auxilium. "We remain committed to protecting and enforcing our
intellectual property rights, and we are currently considering all avenues,
including an appeal." The Full Research Report on Auxilium Pharmaceuticals
Inc. - including full detailed breakdown, analyst ratings and price targets -
is available to download free of charge at:

http://analystscorner.com/microwriter/link.php?s=

http://www.analystscorner.com/r/full_research_report/86a4_AUXL

--

BioTelemetry Inc. Research Report 

On December 4, 2013, Biotelemetry, Inc. (Biotelemetry) (formerly known as
CardioNet, Inc.) announced that the Centers for Medicare and Medicaid Services
has published a reduction to the reimbursement for remote cardiac monitoring
services, effective from January 1, 2014. According to the Company, the
aforesaid reduction will impact all providers of remote cardiac monitoring
services and will result in a 13.7% decrease to the national reimbursement
rate for the MCOT^[^TM^] service. Joseph H. Capper, President and CEO of
BioTelemetry, commented, "We are disappointed that CMS has taken this approach
and will work hard to guide them to a more accurate assessment of the direct
costs associated with these services and to the proven cost savings they
deliver. However, it is important to note that this will not change the
Company's strategic direction." The Full Research Report on BioTelemetry Inc.
- including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:

http://analystscorner.com/microwriter/link.php?s=

http://www.analystscorner.com/r/full_research_report/d815_BEAT

--

Progenics Pharmaceuticals Inc. Research Report

On November 25, 2013, Progenics Pharmaceuticals Inc. (Progenics) announced
that it is re-launching a phase 2b clinical study of safety and efficacy of a
novel targeted radiotherapy, Azedra™, in patients suffering from
pheochromocytomas. Hagop Youssoufian, M.Sc., M.D., Executive Vice President of
Research and Development for Progenics, said, "Azedra has the potential to be
the first approved treatment for pheochromocytomas. Our team is energized by
this opportunity to potentially bring a treatment option with improved dosing,
safety and efficacy to patients suffering with these devastating conditions."
The Company informed that after a successful completion of the phase 2b study,
Progenics intends to submit a New Drug Application (NDA) and request priority
review to receive FDA action on the application within six months instead of
the standard ten. The Full Research Report on Progenics Pharmaceuticals Inc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:

http://analystscorner.com/microwriter/link.php?s=

http://www.analystscorner.com/r/full_research_report/ce17_PGNX

--

Ambit Biosciences Corporation Research Report

On December 3, 2013, Ambit Biosciences Corp. (Ambit Biosciences) announced a
regulatory update after receiving feedback from the US Food and Drug
Administration (FDA) on the development of quizartinib (AC220), the Company's
lead drug candidate, for the treatment of relapsed/refractory acute myeloid
leukemia (AML). The Company informed that based on feedback from the FDA,
Ambit Biosciences continues to move forward with its baseline plan to conduct
a randomized, controlled Phase 3 clinical trial in relapsed/refractory
FLT3-ITD positive AML patients with an overall survival endpoint as the basis
for the potential initial approval of quizartinib. The Company added that it
is continuing to work with the FDA to refine the appropriate starting dose for
the Phase 3 trial. "We remain committed to moving quizartinib through its late
stage development as expeditiously as possible, given the limited treatment
options for FLT3 ITD positive AML patients who have relapsed or who are
refractory to prior treatments," said Michael A. Martino, President and CEO of
Ambit. The Full Research Report on Ambit Biosciences Corporation - including
full detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:

http://analystscorner.com/microwriter/link.php?s=

http://www.analystscorner.com/r/full_research_report/1ff4_AMBI

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Nidhi Vatsal, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

SOURCE Analysts' Corner

Contact: CONTACT PERSON: Joe Thomas CONTACT PHONE: +1-310-496-8071 (North
America
 
Press spacebar to pause and continue. Press esc to stop.